Home
|
About
|
Quick Start
|
FAQ
Beta Version 0.1
DHARA is an online index of articles on Ayurveda published in research journals worldwide.
Users Online:
131
Unfiltered
Classified Search
Enter Keyword Below :
Advanced
Frontiers in pharmacology
2021
May
3;
12
:623795
Withania somnifera (L.) Dunal: Opportunity for Clinical Repurposing in COVID-19 Management
Akash Saggam (1)
,
Akash Saggam (1)
,
Swapnil Borse (2)
,
Swapnil Borse (2)
,
Preeti Chavan-Gautam (2)
,
Preeti Chavan-Gautam (2)
,
Girish Tillu (2)
,
Girish Tillu (2)
,
Bhushan Patwardhan (2)
,
Bhushan Patwardhan (2)
,
Kirti Limgaokar (3)
,
Kirti Limgaokar (3)
,
Santosh Dixit (4)
,
Santosh Dixit (4)
1. AYUSH Center of Excellence, Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India. 2. AYUSH Center of Excellence, Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India 3. Division of Biochemistry, Department of Chemistry, Fergusson College (Autonomous), Pune, Indi 4. Prashanti Cancer Care Mission, Pune, India
Abstract
As the COVID-19 pandemic is progressing, the therapeutic gaps in conventional management have highlighted the need for the integration of traditional knowledge systems with modern medicine. Ayurvedic medicines, especially Ashwagandha (Withania somnifera (L.) Dunal, WS), may be beneficial in the management of COVID-19. WS is a widely prescribed Ayurvedic botanical known as an immunomodulatory, antiviral, anti-inflammatory, and adaptogenic agent. The chemical profile and pharmacological activities of WS have been extensively reported. Several clinical studies have reported its safety for use in humans. This review presents a research synthesis of in silico, in vitro, in vivo, and clinical studies on Withania somnifera (L.) Dunal (WS) and discusses its potential for prophylaxis and management of COVID-19. We have collated the data from studies on WS that focused on viral infections (HIV, HSV, H1N1 influenza, etc.) and noncommunicable diseases (hypertension, diabetes, cancer, etc.). The experimental literature indicates that WS has the potential for 1) maintaining immune homeostasis, 2) regulating inflammation, 3) suppressing pro-inflammatory cytokines, 4) organ protection (nervous system, heart, lung, liver, and kidney), and 5) anti-stress, antihypertensive, and antidiabetic activities. Using these trends, the review presents a triangulation of Ayurveda wisdom, pharmacological properties, and COVID-19 pathophysiology ranging from viral entry to end-stage acute respiratory distress syndrome (ARDS). The review proposes WS as a potential therapeutic adjuvant for various stages of COVID-19 management. WS may also have beneficial effects on comorbidities associated with the COVID-19. However, systematic studies are needed to realize the potential of WS for improving clinical outcome of patients with COVID-19. Keywords: Adjuvant; Ashwagandha; Ayurveda; Cytokine; Immunomodulation; Inflammation; Rasayana.
DHARA ID:
D058243
Pubmed ID:
34012390
Link To Full Paper
Copyright
|
Disclaimer
|
Feedback
|
Updates
|
Contact
Developed and maintained by AVP Research Foundation (Formerly AVT Institute for Advanced Research), 136/137, Trichy Road, Ramanathapuram, Coimbatore - 641045, Tamil Nadu, India
Funded by Central Council for Research in Ayurvedic Sciences, Dept. of AYUSH, Ministry of Health and Family Welfare, Government of India, New Delhi